BIO-TECHNE Corp (TECH) stock
TECHNasdaqBiological Products, (No Diagnostic Substances)Fiscal year ends June 30
Financials through Q1 FY2027, quarter ended Sep 30, 2026Last filing: 10-Q/A on Nov 12, 2026Score 11/3040% above fair value
$72.84+0.04 (+0.05%)
Close on Nov 12, 2026Market cap $11.44BP/E 66.8Yield 0.44%
Bio-Techne operating income
Operating income is the profit from the core business after operating expenses such as R&D and selling costs, before interest and taxes.
Bio-Techne's operating income for the twelve months ending Sep 30, 2026 was $240.84M, up 119.1% year over year. For fiscal 2026 it was $251.89M, up 146.3% from the year before. Over ten years it grew 5.3% a year on average. The highest annual figure on record is $298.94M in fiscal 2023.
Annual operating income
| Period | Period end | Value | Change |
|---|---|---|---|
| FY2026 | Jun 30, 2026 | $251.89M | +146.3% |
| FY2025 | Jun 30, 2025 | $102.26M | -50.5% |
| FY2024 | Jun 30, 2024 | $206.69M | -30.9% |
| FY2023 | Jun 30, 2023 | $298.94M | +0.8% |
| FY2022 | Jun 30, 2022 | $296.59M | +25.0% |
| FY2021 | Jun 30, 2021 | $237.30M | +50.7% |
| FY2020 | Jun 30, 2020 | $157.42M | +7.3% |
| FY2019 | Jun 30, 2019 | $146.72M | +7.7% |
| FY2018 | Jun 30, 2018 | $136.18M | +12.9% |
| FY2017 | Jun 30, 2017 | $120.58M | -19.9% |
| FY2016 | Jun 30, 2016 | $150.59M | +2.4% |
| FY2015 | Jun 30, 2015 | $147.02M | -8.0% |
| FY2014 | Jun 30, 2014 | $159.75M | +100708.4% |
| FY2013 | Jun 30, 2013 | $158.47K | -99.9% |
| FY2012 | Jun 30, 2012 | $166.21M | +1.9% |
| FY2011 | Jun 30, 2011 | $163.06M | +4.3% |
| FY2010 | Jun 30, 2010 | $156.33M | +3.7% |
| FY2009 | Jun 30, 2009 | $150.78M | – |
Quarterly operating income
Change is against the same quarter a year earlier.
Periods
| Period | Period end | Value | Change |
|---|---|---|---|
| Q1 FY2027CQ3 2026 | Sep 30, 2026 | $36.60M | -23.2% |
| Q4 FY2026CQ2 2026 | Jun 30, 2026 | $74.28M | – |
| Q3 FY2026CQ1 2026 | Mar 31, 2026 | $75.50M | +95.0% |
| Q2 FY2026CQ4 2025 | Dec 31, 2025 | $54.46M | +14.9% |
| Q1 FY2026CQ3 2025 | Sep 30, 2025 | $47.66M | +19.2% |
| Q4 FY2025CQ2 2025 | Jun 30, 2025 | -$23.86M | -152.1% |
| Q3 FY2025CQ1 2025 | Mar 31, 2025 | $38.71M | -42.2% |
| Q2 FY2025CQ4 2024 | Dec 31, 2024 | $47.42M | +24.8% |
| Q1 FY2025CQ3 2024 | Sep 30, 2024 | $39.99M | -28.4% |
| Q4 FY2024CQ2 2024 | Jun 30, 2024 | $45.82M | -51.5% |
| Q3 FY2024CQ1 2024 | Mar 31, 2024 | $67.00M | -16.5% |
| Q2 FY2024CQ4 2023 | Dec 31, 2023 | $38.00M | -44.0% |
| Q1 FY2024CQ3 2023 | Sep 30, 2023 | $55.86M | -0.8% |
| Q4 FY2023CQ2 2023 | Jun 30, 2023 | $94.53M | +17.3% |
| Q3 FY2023CQ1 2023 | Mar 31, 2023 | $80.21M | -11.3% |
| Q2 FY2023CQ4 2022 | Dec 31, 2022 | $67.89M | +8.9% |
| Q1 FY2023CQ3 2022 | Sep 30, 2022 | $56.32M | -10.9% |
| Q4 FY2022CQ2 2022 | Jun 30, 2022 | $80.57M | +17.5% |
| Q3 FY2022CQ1 2022 | Mar 31, 2022 | $90.45M | +31.8% |
| Q2 FY2022CQ4 2021 | Dec 31, 2021 | $62.35M | +22.3% |
| Q1 FY2022CQ3 2021 | Sep 30, 2021 | $63.22M | +28.8% |
| Q4 FY2021CQ2 2021 | Jun 30, 2021 | $68.58M | +74.5% |
| Q3 FY2021CQ1 2021 | Mar 31, 2021 | $68.63M | +43.6% |
| Q2 FY2021CQ4 2020 | Dec 31, 2020 | $51.00M | +37.9% |
| Q1 FY2021CQ3 2020 | Sep 30, 2020 | $49.09M | +47.3% |
| Q4 FY2020CQ2 2020 | Jun 30, 2020 | $39.31M | -9.1% |
| Q3 FY2020CQ1 2020 | Mar 31, 2020 | $47.79M | +8.4% |
| Q2 FY2020CQ4 2019 | Dec 31, 2019 | $36.99M | +10.1% |
| Q1 FY2020CQ3 2019 | Sep 30, 2019 | $33.33M | +29.4% |
| Q4 FY2019CQ2 2019 | Jun 30, 2019 | $43.26M | +0.8% |
| Q3 FY2019CQ1 2019 | Mar 31, 2019 | $44.09M | +2.3% |
| Q2 FY2019CQ4 2018 | Dec 31, 2018 | $33.60M | +39.2% |
| Q1 FY2019CQ3 2018 | Sep 30, 2018 | $25.76M | -1.0% |
| Q4 FY2018CQ2 2018 | Jun 30, 2018 | $42.92M | +7.2% |
| Q3 FY2018CQ1 2018 | Mar 31, 2018 | $43.08M | +28.6% |
| Q2 FY2018CQ4 2017 | Dec 31, 2017 | $24.15M | +35.0% |
| Q1 FY2018CQ3 2017 | Sep 30, 2017 | $26.03M | – |
| Q4 FY2017CQ2 2017 | Jun 30, 2017 | $40.05M | – |
| Q3 FY2017CQ1 2017 | Mar 31, 2017 | $33.50M | – |
| Q2 FY2017CQ4 2016 | Dec 31, 2016 | $17.88M | – |
See a number that looks wrong?